论文部分内容阅读
为探讨上颌窦癌早期诊断及预后的免疫学指标,采用酶联免疫吸附法,对45例早期上颌窦癌患者及67名健康人检测了血清可溶性白细胞介素-2受体(sIL-2R)、肿瘤坏死因子(TNF)含量。结果表明,上颌窦癌组血清sIL-2R和TNF的含量分别为455±31.2U/ml和106±15.3μg/ml,均显著高于健康人组的396±26U/ml和67±5.6μg/ml,P<0.01;并显著高于治疗后的401±27U/ml和72±11μg/ml,P<0.05。随访3年,每2～3个月检测一次血清sIL-2R和TNF含量,9名上颌窦癌患者复发,其sIL-2R、TNF含量分别为448±29U/ml和98±13μg/ml,显著高于健康人组及治疗后水平,P<0.05,且该变化比肉眼发现的复发早2个月。结论:血清sIL-2R和TNF含量是上颌窦癌疗效观察及预测复发的敏感的免疫学指标。
In order to explore the immunological parameters of early diagnosis and prognosis of maxillary sinus cancer, serum soluble interleukin-2 receptor (sIL-2R) was detected in 45 patients with early maxillary sinus cancer and 67 healthy persons by enzyme-linked immunosorbent assay (ELISA) , Tumor necrosis factor (TNF) content. The results showed that the levels of serum sIL-2R and TNF in maxillary sinus cancer group were 455 ± 31.2U / ml and 106 ± 15.3μg / ml, respectively, which were significantly higher than those of 396 ± 26U / ml and 67 ± 5.6μg / ml, P <0.01; and significantly higher than 401 ± 27U / ml and 72 ± 11μg / ml after treatment, P <0.05. Serum levels of sIL-2R and TNF were measured every 2 to 3 months after follow-up for 3 years. The recurrence rate of 9 maxillary sinus cancer patients was 448 ± 29U / ml and 98 ± 13μg / ml, respectively Higher than the healthy group and after treatment level, P <0.05, and the change was 2 months earlier than the naked eye found. Conclusion: The serum sIL-2R and TNF levels are the sensitive immunological indicators for the treatment of maxillary sinus cancer and prediction of recurrence.